Ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) potentiator indicated for the treatment of cystic fibrosis in patients with specific gating mutations. This category encompasses… Read more



































Ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) potentiator indicated for the treatment of cystic fibrosis in patients with specific gating mutations. This category encompasses essential reference standards, including the active pharmaceutical ingredient, critical metabolites, degradation products, and stable isotope labelled compounds required by pharmaceutical laboratories for rigorous analytical testing, method validation, and quality control. Impurities arising from pathways such as hydrolysis, oxidation, and photolysis must be accurately identified to ensure safety and stability. Consequently, these standards are vital for comprehensive impurity profiling and adhering to regulatory guidelines. Furthermore, stable isotope labelled versions serve as indispensable internal standards for mass spectrometry-based assays, allowing for precise quantification during pharmacokinetic studies. By providing both pharmacopeial and non-pharmacopeial materials, this selection supports the robust characterization, long-term stability monitoring, and consistent quality assurance of this complex therapeutic agent.